Pharmaceuticals
2015: No.22 - £160m
2014: No.43 - £75m
are the biggest winners in this year’s Rich List following the impressive strides made by their Burton-on-Trent based pharmaceutical company Clinigen.
When Clinigen was floated on the AIM market in September 2012 it was hailed as one of the best stock market launches of the year. Since then profits have soared.
READ MORE: {}
The £135 million flotation meant a windfall for Andrew and Linda Leaver .
They retained a £47 million stake in the group which Andrew Leaver, 51, formed in 2010, bringing together Keats Healthcare, Clinigen GAP and Clinigen SP.
In the 12 months to June 30, 2014, profits jumped by 47 per cent. The firm reported a profit of £21.3 million compared to £14.5 million the previous year. Revenue was up three per cent to £126.6 million.
The trend continued for the rest of the year with revenues to the end of December up 17 per cent to £72.6 million. Gross profit was up by 11 per cent and net cash more than doubled to £12.9 million.
In the year Clinigen shipped 58,000 units of drugs to more than 75 countries – an 87 per cent increase which has come off the back of growth in exisiting programmes and new programmes.
Most Read
Clinigen’s product lines increased from three to five following the acquisition of two oncology support products: Savene in March and Ethyol from AstraZeneca in August.
The company was set up to .
It quickly developed into a global provider of specialist pharmaceutical products and services and in 2011 was hailed as the fastest growing private company in the 海角视频 in the Sunday Times Fast Track 100.
The company is currently trialling a drug designed to counteract the effects of MRSA-related infections.
The drug has the potential to make a huge difference to critically ill patients.
Now it has outlets in Tokyo and Philadelphia, as well as its headquarters and a distribution centre in Burton.
The company has a fast growing customer base of pharmaceutical companies, biotechnology specialists and research organisations.
Don’t miss
Keats Healthcare has been rebranded as Clinigen CTS, dedicated to sourcing and supplying commercial medicines for clinical study.
Clinigen GAP provides pharmaceutical consultancy and development while Clinigen SP concentrates on specialist pharmaceuticals and hospital-only medicines worldwide, commercialising them in niche markets.
In October the company received a top US award for making a pioneering new drug – Foscavir – more widely available.
The US Food and Drug Administration said the company had resolved a critical drug shortage, and was also praised for its quality and manufacture.
In April the group secured a new four year £35 million multi-currency revolving credit facility from Royal Bank of Scotland to enable it to continue its worldwide growth.